Loading...
  • Acute Leukemia
  • CNS prophylaxis: When blood counts recover, patients with acute leukemia or chronic myelogenous leukemia in blastic crisis resume IT methotrexate once every 2 weeks for a total of 4 doses (including the dose given before the conditioning regimen) and leucovorin calcium IV or orally 4 hours after (each dose of methotrexate) and every 6 hours for a total of 8 doses. (clinicaltrials.gov)
  • Leukaemia
  • In the last few years he has been responsible for the Australasian Leukaemia and Lymphoma Group's clinical trial program in acute promyelocytic leukaemia (APL), and has combined this with an active laboratory program in the molecular analysis of APL cells. (edu.au)
  • leukemic cells
  • Although the leukemic cells of family members sometimes express the same immunoglobulin (Ig) heavy-chain variable region gene , the cells of each patient have different Ig heavy-chain variable region genes [13,17, (cancernetwork.com)
  • with the use of G-banding and Q-banding techniques, almost 50% of the leukemic cells of CLL patients have been found to have clonal chromosomal abnormalities [19- (cancernetwork.com)
  • therapeutic
  • New therapeutic modalities such as nucleoside analogs and bone marrow transplantation have improved response rates in CLL and create expectations about potential cure of this disease. (cancernetwork.com)
  • A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. (jcancer.org)
  • lymphoma
  • Aggressive mantle cell lymphoma in first complete remission. (knowcancer.com)
  • To progres studies in Oncodermatology , he is building strong links with the Westmead Cancer Care Centre and the Skin and Cancer Foundation Australia, opened the first Cutaneous Lymphoma Clinic and cutaneous Graft versus Host Disease Clinics in NSW, and he is participating in melanoma, cutaneous lymphoma, basal cell carcinoma, non-melanoma skin cancer, and actinic keratosis clinical trials. (edu.au)
  • Giving dendritic cell therapy, cryosurgery and pembrolizumab may work better at treating non-Hodgkin lymphoma. (mayo.edu)
  • dendritic cell
  • He is also a member of the Dendritic Cell Biology and Therapeutics Group at the Anzac Research Institute, and, with Professor Derek Hart, is involved in developing new approaches for treatment of graft-versus-host disease based on a better understanding of the role of dendritic cells in this disease. (edu.au)
  • Vaccines, such as dendritic cell therapy made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. (mayo.edu)
  • interfere
  • Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. (mayo.edu)
  • disease
  • Several prognostic factors were associated with response, including: a limited number of metastatic sites, exclusive lung metastases, clear cell histology and "slow" progressive disease. (jcancer.org)